Drug Type Monoclonal antibody |
Synonyms HTI-1088, HTI-1316, SHR 1316 + [2] |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (28 Feb 2023), |
RegulationSpecial Review Project (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Extensive stage Small Cell Lung Cancer | China | 28 Feb 2023 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscle Invasive Bladder Carcinoma | Phase 3 | China | 25 Apr 2025 | |
Advanced Hepatocellular Carcinoma | Phase 3 | China | 28 Oct 2024 | |
Non-squamous non-small cell lung cancer | Phase 3 | China | 29 Mar 2024 | |
Non-squamous non-small cell lung cancer | Phase 3 | China | 29 Mar 2024 | |
Small cell lung cancer limited stage | Phase 3 | China | 20 Jan 2021 | |
Non-small cell lung cancer stage IIIB | Phase 3 | China | 14 Jul 2020 | |
Resectable Lung Non-Small Cell Carcinoma | Phase 3 | China | 10 Jul 2020 | |
Unresectable Biliary Tract Carcinoma | Phase 2 | - | 10 Jul 2025 | |
Neoplasm Metastasis | Phase 2 | China | 01 Jul 2025 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | China | 01 Jul 2025 |
Phase 2 | 31 | odvdoyjsbs(tkxefkhroj) = ybsfbfpjha ypzhccbqxg (goffdjgmms ) View more | Positive | 03 Jul 2025 | |||
NCT04303988 (ASCO2025) Manual | Phase 2 | 35 | rbmihwdcqb(hahfoeercp) = vajuhomunl txkixjdmdj (lkxxgocuwv ) View more | Positive | 30 May 2025 | ||
Phase 2 | 10 | awxbsvfpnu(wmhnetrpbj) = mxqacmquxw xlcsegwroo (nscsbifubi ) View more | Positive | 30 May 2025 | |||
Phase 2 | 30 | gkewewfgwg(ntaapgtuhx) = ctvxtgidta nkxcgcbvnq (iomwgakbfv ) View more | Positive | 30 May 2025 | |||
Phase 2 | - | ekfkghwcmh(wvztjxnfcv) = idelmzryhm xvlvamycqm (xtoifrgxjh ) View more | - | 26 Mar 2025 | |||
Not Applicable | 75 | inusrmgpwa(bfjsbkqgcv) = uahmyrirln lisvzuvmvh (czbnhydhgo, 54.8 - 77.1) View more | Positive | 26 Mar 2025 | |||
Phase 2 | 36 | Adebrelimab + Chemotherapy | cjribwustu(bwopllrjey) = pcxephxzng fohfcnfnzn (padbaxeilg, 23.1 - 56.5) View more | Positive | 23 Jan 2025 | ||
Adebrelimab + Chemotherapy (Surgery) | cjribwustu(bwopllrjey) = usogghldby fohfcnfnzn (padbaxeilg, 24.6 - 59.3) View more | ||||||
Phase 2 | Locally Advanced Esophageal Squamous Cell Carcinoma Adjuvant | Neoadjuvant | 36 | Adebrelimab + Paclitaxel + Cisplatin | klbhmgkkku(uwktmmmmxr) = anxgmhaocg wcfdzrdweg (jeqxlpcpdw ) View more | Positive | 23 Jan 2025 | |
Phase 2 | Gastroesophageal junction adenocarcinoma Neoadjuvant | 15 | rraetqcrlv(vtyiynmkry) = ylkgmzjgtb tnlmllomiy (mimzvuyvan ) View more | Positive | 12 Dec 2024 | ||
ESMO_IO2024 Manual | Not Applicable | Extensive stage Small Cell Lung Cancer First line | 188 | Adebrelimab-based regimen | zmlseahbdu(lmrhrdzvqh) = fbrglktpfw njrztwrenf (gzeuxdooyy ) View more | Positive | 12 Dec 2024 |